Skip to main content

Table 1 Baseline characteristics of the study groups: Japanese data

From: Interleukin-6: a new therapeutic target

   Tocilizumab
Characteristic Placebo 4 mg/kg 8 mg/kg
n 53 54 55
Age (years) 53 54 56
Sex (male/female) 14/39 14/40 9/46
RA duration (years) 8.4 7.3 8.3
Previous DMARD use 5 4 5
Tender joint count 18 ± 8 19 ± 9 18 ± 10
Swollen joint count 14 ± 6 16 ± 9 14 ± 7
ESR (mm/hour) 69 ± 31 71 ± 29 67 ± 31
CRP (mg/dl) 5.5 ± 4.2 4.7 ± 2.9 4.5 ± 3.3
  1. CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis. Adapted, with permission, from [12].